Trabectedin maintenance therapy after liposomal doxorubicin plus trabectedin combination in patients with relapsed ovarian cancer: the randomized, phase II TRAMANT study

The results suggest that TRB may be a viable maintenance option for patients with relapsed ovarian cancer, providing a sustained response with favorable tolerability. Nonetheless, the small sample size underscores the need for further research to validate these findings. Studies with larger cohorts are necessary to confirm these results and optimize treatment strategies for recurrent ovarian cancer.

Authors

Institutions

Publication Details

Journal
International Journal of Gynecological Cancer
Published
2025-05-24
DOI
https://doi.org/10.1016/j.ijgc.2025.101950
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Trabectedin maintenance therapy after liposomal doxorubicin plus trabectedin combination in patients with relapsed ovarian cancer: the randomized, phase II TRAMANT study

Valentina Tuninetti, Claudio Zamagni, Paolo Scollo, Giovanni Scambia et al.
International Journal of Gynecological Cancer
Ovarian cancer diagnosis and treatment
article

Trabectedin maintenance therapy after liposomal doxorubicin plus trabectedin combination in patients with relapsed ovarian cancer: the randomized, phase II TRAMANT study

Valentina Tuninetti, Claudio Zamagni, Paolo Scollo, Giovanni Scambia, Carmine De Angelis, Elena Geuna, Giuseppe Scibilia, Vanda Salutari, Giuseppa Scandurra, Antonio Ardizzoia, Simona Scalone, Giorgio Valabrega, Valentina Lombardo, Antonella Savarese
article en

Abstract

The results suggest that TRB may be a viable maintenance option for patients with relapsed ovarian cancer, providing a sustained response with favorable tolerability. Nonetheless, the small sample size underscores the need for further research to validate these findings. Studies with larger cohorts are necessary to confirm these results and optimize treatment strategies for recurrent ovarian cancer.

International Journal of Gynecological CancerVol. 36(2)
Università degli Studi di Enna Kore (IT), Agostino Gemelli University Polyclinic (IT), Alessandro Manzoni Hospital (IT), Federico II University Hospital (IT), Azienda USL di Bologna (IT), Centro di Riferimento Oncologico (IT), A. O. Ordine Mauriziano di Torino (IT), National Cancer Institute (MY), Ospedale Cannizzaro (IT), Candiolo Cancer Institute (IT)
Good health and well-being
Openalex Percentile: Top 84%
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.